EFFICACY, SAFETY AND COMPLIANCE OF TERAZOSIN IN THE TREATMENT OF PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA.
AbstractBackground: The primary objective of this study was to determine the efficacy, safety and compliance of terazosin, aselective long-acting alpha 1-blocker, for the treatment of symptomatic BPH. Methods: A total of 150 patients rangingin age between 45 and 81 years with symptomatic BPH were included. They were randomly assigned to receiveterazosin (n =74) or placebo (n = 76) for 12 weeks. Results: Terazosin significantly improved urinary symptoms versusplacebo, assessed by using the 1-PSS (-30vs. -17%, P=0.007). Maximum flow rate increased significantly withterazosin (2.3 ml/s i.e. ± 28%) compared with placebo (1.1 ml/s i.e. ±13%, P=0.006). Residual urine was alsosignificantly reduced with terazosin. Overall, terazosin was as well tolerated as placebo. Seven patients werewithdrawn from the study for adverse events with terazosin (9.45%) and eight patients (10.52%) with placebo. Theincidence of vasodilatation-related events like postural symptoms, dizziness, headache with terazosin was similar(8.11%) to that of placebo (7.90%). The reduction in supine blood pressure was minor (< 5mm Hg), both innormotensive and hypertensive patients. Conclusion: This study demonstrates the efficacy, safety and compliance ofterazosin for the treatment of BPH.
Berry, S.J., Coffery, D. S., Walsh, P.C. and Ewing,
L; The development of human benign prostatic
hypertrophy with age. J. Urol., 1984;132:474-
Rutkow. I.M.: Urological operations in the United
States, 1979-1984. J. Urol., 1986; 13 5:1206
Turner-war wick, R., Whiteaide, C.G., Arnold,
E.T.et al.: A Urodynamic view of prostatic
obstruction and results of prostatectomy. Br. J.
Ball, A.J.; Feneley, R.C. L and Abrams, P.H.: The
natural history of untreated “prostatism”.
Cockett, A. T.K., Aso, Y., Denis, L.et.al.:
Recommendations of the International Consensus
Committee Concerning: 4.BPH treatment
recommendations. Im Cocktt, A.T.K. et. al.
Editors. The 2nd International Consultations on
Benigin Prostatic Hyperplasia(BPH), Paris,
Caine, M: Alpha-adrenergic blockers for the
treatment of benign prostatic hyperplasia. Urol.
Lepor, H., Shapiro, E., Gup, D.I. et. al.:
Laboratory assessment of terazosin and alpha 1
blockade in prostatic hyperplasia. Urology,
Lepor, H.: Pharmacologic management of benign
prostatic hyperplasia. In:1992: Urology Annual.
Edited by Rous, S.N., Norwalk, 1991,PP. 1 -19.
Caine, M., Pfau, A. and Perlbery.S.: The use of
alpha- adrenergic blockers in benign prostatic
Hedlund, H. and Andersen, K.E., Ek. A.: Effects
of prazosin in patients with benign. prostatic
obstruction. J.Urol.,1983; 130:275.
Lacorow, J.W. and Dunn, M.: Indoramin: An
effective new drug in the management of bladder
outflow obstruction.Br.J.Urol.,1987; 60:526.
Ramsay, J.W. A., Scott, G. l. and Whitfield, H. N.:
A double-blind controlled trial of a new alpha 1
blocking drug in the treatment of bladder outflow
obstruction. Br. J. Urol., 1985;57:657.
Caine, M., Mazouz, B. and Rossini, B.M.: The
effect of nicergoline on the lower urinary tract
muscle. Urol.Res., 1984; 12:287.
Anderson, K. E., Hedlund, H., Larsson, B et. al.:
Ketanserine interaction with urethral alphaadrenoreceptors. J. Urol., 1987. 37:534.
JAMC, Vol. 12, No. 2, 2000
Lepor. H., Baumann, M. and Shapiro, E.: The
alpha-adrenergic binding properties of terazosin
in the human prostate adenoma and caine brain.
Dunzendrofer, U.: Clinical experience.
Symptomatic management of BPH with terazosin
therapy. Urology. 1988;32 (Suppl.): 27.
Lipsitz, L. A.: orthostatic hyperplasia in the
elderly. New Engl.J.med.,1989;321:952.
Chappie, C.R., Carter, P., Christmas, T. J. et. al.:
A three-month double blind study of doxazosin as
treatment of benign prostatic bladder outlet
Lepor, H., Meretyk, S. and Knapp-.Maloney. G:
The safety, efficacy and compliance of terazosin
thrapy for benign prostatic hyperplasia. J. Urol.,
Lepor, H., Auerbach, S., Puras-Baez, A. et. al.: A
randomized, placebo controlled multicenter study
of the efficacy and safety of terazosin in the
treatment of benign prostatic hyperplasia. J.
Urol., 1992; 148:1467-1474.